Instituto Nacional de Rehabilitacion   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Mexico City Mexico (1951)

Organization Overview

First Clinical Trial
2013
NCT01826422
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Instituto Nacional de Rehabilitacion

Active Ingredients

Drugs in Phase 3 Trials (1)

allopurinol (zyloprim) (1 trial)

Drugs in Phase 2 Trials (2)

fish oil (Omegavan) (1 trial)

icosapent ethyl (vascepa) (1 trial)

Drugs in Phase 1 Trials (2)

bromhexine (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

Drugs in Other Trials (1)

l-glutamine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperuricemia (Phase 3)

Inflammation (Phase 3)

Metabolic Diseases (Phase 2)

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 6